Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPresbyterian Health Plan Prescription Formulary Co…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentPresbyterian Health PlanPolicy N/A

    Commercial 4-Tier Prescription Drug Formulary — Coverage Criteria

    Customize your policy alerts

    Sign up for all Presbyterian Health Plan policy alerts

    Know when Presbyterian Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Presbyterian Health Plan and Presbyterian Insurance Company Commercial 4-tier formulary structure, management processes (prior authorization, step therapy, quantity limits), and member/provider processes for exceptions and inquiries; applies to commercial plan members and providers in the plan's service area.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyCommercial 4-Tier Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation (including diagnosis validation and applicable NDC) when a product is annotated with PA or DX.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Formulary tiers (Tier 1-4)
    72hStandard PA processing time (when complete)
    24hExpedited PA processing time
    $25Preferred insulin copay cap
    multipleListed with PA requirement
    biologicsDX / SP flags present

    Coverage Criteria and Product-Level Controls

    General Medical Necessity and Prior Authorization

    Covered when ALL of the following are met:

    Formulary coverage general criteria: Drug is a covered benefit under the member's specific plan AND prior authorization (if required) is approved based on medical necessity and appropriateness.

    Medical Director or other clinical professional will review PA requests; non‑Formulary drugs require medical exception documentation.

    Formulary utilization management controls

    Products listed on the formulary are subject to the utilization management controls shown on each product line; coverage requires adherence to those controls.

    UM flag adherence: If a formulary line includes any of the following notes, coverage requires compliance with that control: PA (Prior Authorization), DX (Diagnosis Validation), QL (Quantity Limit), AL (Age Limit), ST (Step Therapy), NDS, SP (Specialty Pharmacy), or CB (Copay Cap).

    Apply per‑product as annotated in the formulary entries.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyCommercial 4-Tier Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation (including diagnosis validation and applicable NDC) when a product is annotated with PA or DX.
    SourceLink
    On This Page
    Coverage Criteria and Product-Level ControlsFormulary Entries, Codes, and Quantity Limit ExamplesPrior Authorization, Step Therapy, Documentation, and Denial RisksInitiation and Pediatric Initiation ControlsStep Therapy Rules and ExamplesQuantity Limits and Per-Product ExamplesSite of Care and Specialty Pharmacy HandlingKey Terms and AbbreviationsFormulary Purpose and Policy ScopeBiosimilar Coverage Notes

    Product-specific coverage criteria (examples)

    Coverage of listed formulary drugs is governed by the product-specific utilization management notes shown next to each formulation (examples):

    Acetaminophen–codeine products (pediatric rules): Not covered for patients under 12 years of age; for patients age 12–18 years prior authorization is required; quantity limits apply as noted (e.g., QL 166 mL per 1 day for some solutions; QL 13 EA per 1 day for tablets).age <12 => not covered; age 12-18 => PA

    See formulary product lines for exact QL and AL values.

    Butalbital-containing combinations: Certain butalbital combinations require prior authorization for minors (12–18) and are not covered under 12; quantity limits (e.g., QL 6 EA per 1 day) apply per formulation.age <12 => not covered; age 12-18 => PA

    Apply product-specific Notes.

    Extended‑release opioid formulations: Some ER opioid products are subject to step therapy (ST) and quantity limits; Schedule II products are limited to a maximum 34‑day supply where noted.Schedule II => max 34-day supply

    Follow ST and QL flags on product lines.

    MOUD and buprenorphine products: Buprenorphine and related MOUD products may be flagged BH (behavioral health), have age limits and quantity limits, and may require specialty pharmacy handling (SP); coverage follows those annotations.varies by product

    See specific product Notes for QL and AL.

    Formulary coverage logic

    Coverage is determined by formulary tier and the utilization-designation flags shown on each line item:

    Formulary coverage logic: Coverage follows the assigned formulary tier; products annotated with PA require prior authorization before coverage, ST indicates step therapy edits that require documented trial/failure of prerequisite agents, QL indicates an allowable quantity per timeframe, and AL denotes minimum/maximum age restrictions. BH notes may indicate behavioral‑health zero cost‑share where applicable.

    Providers must supply required documentation (PA, DX, evidence of step failure, etc.) when submitting requests.

    Insulin products

    Insulin products are covered according to tier, copay cap, and quantity limits as listed:

    Preferred insulin coverage: Preferred formulary insulins (Tier 2 entries) are covered with a copay cap (CB) not to exceed $25.00 per 30‑day supply for eligible plans; High Deductible Health Plan members remain subject to deductible rules.CB <= $25 per 30 days

    Document on claim/PA as required.

    Insulin quantity limits: Insulin pen/cartridge/solution QLs are applied per product (common examples: QL 45 mL per 30 days or QL 50 mL per 30 days; select U‑500 products have distinct QLs such as 18 mL per 30 days).QL examples: 45-50 mL per 30 days

    Follow the specific product QL in the formulary line.

    GLP-1/GIP agents

    Incretin mimetic agents (GLP‑1 and GIP) are subject to utilization controls as annotated:

    GLP‑1/GIP coverage: Selected incretin mimetic agents (e.g., Mounjaro, Trulicity) require prior authorization (PA) and are subject to quantity limits (example QL 2 mL per 28 days); some entries include NDS or other plan flags.QL 2 mL per 28 days

    PA required where noted on the formulary line.

    Oral antidiabetics and combinations

    Oral antidiabetic agents and combinations are managed with tiering and utilization edits:

    Oral antidiabetic utilization: Multiple oral antidiabetic agents and combinations are assigned tiers and may require step therapy (ST) and quantity limits (examples: Steglujan marked ST with QL 30 EA per 30 days; dapagliflozin noted ST and QL 30 EA per 30 days).varies by product

    Follow ST and QL flags per product line.

    Supportive and specialty medications

    Supportive, antidote, antiemetic, and antifungal medications have product-level UM annotations:

    Supportive and specialty agents: Naloxone, naltrexone/Vivitrol, antiemetics (ondansetron, palonosetron, aprepitant/Emend/Cinvanti) and antifungals (echinocandins, Ambisome, voriconazole) are listed with tiers and may require prior authorization (PA), quantity limits (QL), or be designated MB or SP per the formulary line.varies

    Refer to each product line for PA/QL/MB/SP specifics (e.g., naloxone QL 2 mL per 30 days; Vivitrol QL 1 EA per 28 days; Emend IV = PA).

    Formulary utilization controls

    Formulary utilization controls summarized for provider guidance:

    Utilization control summary: Products annotated with PA require prior authorization; products with QL are limited to the specified quantity per timeframe; ST indicates step therapy edits requiring documented trials of prerequisite agents; AL indicates age limits; NDS and SP indicate other plan-specific handling; BH indicates behavioral health zero cost‑share may apply; STI indicates zero cost‑share when used for STI prevention/treatment per benefit rules.

    Providers must follow the annotations on each formulary line when submitting claims or PA requests.

    Formulary product-level coverage rules

    Coverage and restrictions are listed per product — follow the product line entry for the exact combination of tier and utilization flags:

    Per‑product coverage rules: Each formulary product line assigns a tier and may include notes such as PA, QL, AL, BH, DX (diagnosis validation), SP, NDS, or CB; coverage and approval depend on meeting those annotations and any documentation requirements.

    See individual product entries for required documentation (e.g., DX for biologics, PA for injectables).

    Contraceptives - coverage and copay notes

    Contraceptive products are covered with specific supply and copay guidance:

    Contraceptive coverage: Multiple contraceptive formulations (oral, transdermal, vaginal ring, IUD, injectable, emergency contraceptives) are listed with tiering; many carry a '$0 Copay per PPACA guidelines' note and 'Up to a six‑month supply' where indicated.Up to 6 months supply where noted

    Apply PPACA $0 Copay notes per benefit plan rules; documentation of supply may be required.

    Steroids and cough/cold - coverage notes

    Selected corticosteroids and cough/cold products have quantity and age-based restrictions:

    Steroids and cough/cold coverage notes: Budesonide delayed‑release capsules have an annual QL (e.g., QL 448 EA per 365 days); certain cough/cold codeine‑containing or guaifenesin‑codeine products are not covered for patients under 12 years and require prior authorization for ages 12–18.Budesonide QL 448 per 365 days; cough/cold age rules: <12 not covered; 12-18 => PA

    Follow product line entry for exact QL and AL values.

    Presbyterian Health Plan maintains a closed Formulary: the Formulary is a continually updated preferred drug list intended to encourage safe, effective, and cost‑efficient medication use. Non‑Formulary drugs are not routinely reimbursed and require a medical exception showing medical necessity for coverage; the medical exception process is the route to request coverage of non‑Formulary medications.

    Benefit exclusion designations identify drugs that are not a covered benefit under the plan and therefore are not eligible for reimbursement regardless of clinical justification unless otherwise specified by separate benefit language.

    Within the extracted formulary segments there are no additional, explicit categorical exclusions listed; instead coverage is governed at the product level by tiering and utilization management notes (e.g., PA, QL, ST, AL) shown on individual line items.

    Certain codeine‑, tramadol‑, and related combination cough/cold and analgesic products are explicitly not covered for patients under 12 years of age. For patients aged 12–18 years these products require prior authorization (PA) before coverage; consult the individual product line note for the specific PA and quantity limit (QL) that applies.

    Formulary entries include the product’s tier and an associated Notes field; Notes commonly indicate utilization controls such as PA (prior authorization), ST (step therapy), QL (quantity limits), AL (age limits), and benefit flags (e.g., BH, $0, MB).

    Preferred insulin products carry a copay cap (CB) of $25 per 30‑day supply when noted as the preferred formulary insulin; many insulin and specialty lines also list specific QLs (for example, common insulin QLs of 45 mL or 50 mL per 30 days) which must be followed and documented on claims or prior authorization submissions.

    Formulary Entries, Codes, and Quantity Limit Examples

    Formulary drug entries (selected)mixed
    palonosetron hcl intravenous solution 0.25 mg/2mlpalonosetron hcl IV solution 0.25 mg/2ml — Tier = MB; Notes = QL (2 ML per 5 days).
    caspofungin acetate intravenous solution reconstituted 50 mgcaspofungin acetate IV solution reconstituted 50 mg — Tier = MB; Notes = listed under ECHINOCANDINS.
    caspofungin acetate intravenous solution reconstituted 70 mgcaspofungin acetate IV solution reconstituted 70 mg — Tier = MB; Notes = listed under ECHINOCANDINS.
    promethazine hcl injectionpromethazine hcl injection — formulary entry (injectable) with corresponding notes where applicable.
    promethazine hcl oralpromethazine hcl oral formulations (tablet/syrup) — formulary entry where applicable.
    promethazine hcl rectalpromethazine hcl rectal formulation (suppository) — formulary entry where applicable.
    REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/MLREPATHA subcutaneous solution prefilled syringe 140 mg/mL — product-level entry (ensure covered NDCs / PA/QL per biologic section where applicable).
    amlodipine benazepril combinationamlodipine benazepril combination products — ACE/ARB combination entries included in formulary (ensure corresponding tier/QL if present).
    ACE/ARB/HCTZ combinationsACE/ARB/HCTZ combination products — combination antihypertensive entries included in formulary.
    vancomycin hcl IV reconstituted 500 mgvancomycin hcl IV reconstituted 500 mg — IV formulation entry (parenteral).
    1–10 of 15
    1/2
    Covered biologic NDC examplesNDCCovered
    AMJEVITA 40 MG/0.4ML auto-injectorCovered NDCs: 55513-0482-01, 55513-0482-02; QL (1.6 ML per 28 days).
    AMJEVITA 40 MG/0.8ML auto-injectorCovered NDCs: 72511-0400-01, 72511-0400-02; QL (3.2 EA per 28 days).
    AMJEVITA 80 MG/0.8MLCovered NDCs: 55513-0481-01, 55513-0481-02; QL (1.6 ML per 28 days).
    AMJEVITA 40 MG/0.4ML prefilled syringeCovered NDCs: 55513-0479-01, 55513-0479-02; QL (1.6 ML per 28 days).
    HUMIRA (2 PEN) 40 MG/0.4MLCovered per listed NDCs where applicable; QL (2 EA per 28 days).
    KEVZARA 150 MG/1.14ML prefilled syringeCovered examples with QL (2.28 ML per 28 days).
    REPATHA 140 MG/ML prefilled syringeREPATHA (evolocumab) prefilled syringe 140 mg/mL — ensure covered NDCs referenced in product list where applicable.
    Regulatory scheduling notemixed
    Schedule II supply limitSchedule II medications are limited to a 34 day supply maximum (as noted on morphine sulfate ER entries).
    Quantity Limits and Notes examplesmixed
    QL (30 EA per 30 days)Multiple stimulant entries (e.g., amphetamine-dextroamphetamine) — QL (30 EA per 30 days) and variations present.
    QL (60 EA per 30 days)Various formulations show QL (60 EA per 30 days) per line.
    QL (90 EA per 30 days)Some agents list QL (90 EA per 30 days).
    QL (120 EA per 30 days)Higher QL examples (e.g., lamotrigine ER lines).
    QL (50 ML per 30 days)Insulin/solution ML-based QL examples (e.g., HUMALOG QL 50 ML per 30 days).
    QL (45 ML per 30 days)Insulin QL examples (45 ML per 30 days) as listed for several insulin pens/solutions.
    QL (2 ML per 5 days)Palonosetron IV QL example: QL (2 ML per 5 days).
    QL (1.6 ML per 28 days)Biologic ML-based QL examples for AMJEVITA and others.
    QL (3.2 EA per 28 days)Biologic EA-based QL examples (AMJEVITA 0.8 mL autoinjector).
    QL (448 EA per 365 days)Example QL (448 EA per 365 days) appears with budesonide oral capsule entry and is included here.
    1–10 of 15
    1/2
    No procedure or billing codesmixed
    No codes listed
    Formulary drug lines (no billing codes in excerpt)mixed
    metformin entriesMetformin ER and regular tablet lines included under BIGUANIDES.
    insulin product entriesHumalog, Humulin, Lantus and others with CB copay cap notes and QL (45-50 ML per 30 days) present.
    Formulary product entries (partial)mixed
    ondansetron oral dispersible 4 mg/8 mgondansetron oral tablet dispersible 4 mg, 8 mg — QL (90 EA per 30 days).
    palonosetron hcl IV 0.25 mg/2mlpalonosetron hcl IV 0.25 mg/2ml — Tier = MB; QL (2 ML per 5 days).
    aprepitant oral capsuleaprepitant oral capsule 125 mg, 40 mg — PA; QL (1 EA per 30 days).
    Selected urinary/antimalarial entriesmixed
    nitrofurantoin productsNitrofurantoin macrocrystal and monohydrate forms included; oral suspension QL noted.
    chloroquine phosphate 250/500 mgChloroquine phosphate oral tablet 250 mg, 500 mg included.
    hydroxychloroquine sulfate 200 mgHydroxychloroquine oral tablet 200 mg included.
    Selected antineoplastic/targeted therapy entriesmixed
    REPATHA 140 mg/mLREPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML noted among biologic entries — ensure PA/coverage per policy where applicable.
    various antineoplasticsMultiple antineoplastic agents listed with PA/QL/DX requirements (e.g., ALECENSA, ALUNBRIG, KEYTRUDA QLEX).
    Diagnosis codes referencedICD-10
    DX (Diagnosis Validation Required)Many biologic and antineoplastic entries require diagnosis validation at point of sale or prior authorization.
    Quantity-limit statements (formulary lines)mixed
    QL examplesConsolidated QL statements preserved (30/60/90 per 30 days, ML per 28/30 days, EA per 365 days such as 448 EA per 365 days).
    Quantity limits — examplesmixed
    QL (2 ML per 5 days)palonosetron IV QL example preserved.
    QL (448 EA per 365 days)Budesonide oral capsule QL example preserved.
    QL (50 ML per 30 days)Insulin copay cap QL examples preserved (50 ML/HUMALOG etc.).

    Prior Authorization, Step Therapy, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for many specific formulary products including select biologics, specialty and oncology agents, certain antivirals/hepatitis agents, select opioids and cough/cold preparations for pediatric ages, and other listed drugs. When a drug entry includes a PA note or PA flag, prescribers must submit a Prior Authorization request and supporting clinical documentation. PA requests are reviewed by a Medical Director or other clinical professional to determine medical necessity and benefit coverage; PA approval does not guarantee payment if coverage ends before service delivery.

    • PA required when 'PA' appears in formulary Notes for the product.
    • Many biologics/specialty agents require both PA and diagnosis validation (DX) and may restrict to covered NDCs — provide NDC when requested.
    • PA applies to numerous oncology and antineoplastic agents; diagnosis validation (DX) is commonly required at PA or point of sale.
    • Select antiviral/hepatitis agents (e.g., MAVYRET, sofosbuvir-velpatasvir, entecavir, valganciclovir) require PA and may have QL/NDS/SP flags.
    • Some injectables/long-acting therapies (e.g., ABILIFY MAINTENA, CABENUVA, SPRAVATO) require PA and have quantity and age limits.
    • Select opioids and codeine-containing cough/cold products are subject to PA and pediatric age-based coverage limits (not covered under certain ages; PA required for adolescents).
    • Schedule II controlled medications are limited to a 34-day supply maximum where noted.
    • PA approvals may require prescriber-supplied clinical information, diagnosis codes, prior trials (for step therapy), and covered NDCs for product-specific coverage.
    • If required PA, DX, QL, ST, BH, CB or AL notes are not followed or documentation is missing, requests may be denied.
    • Expedited PA requests are processed within 24 hours when delay could jeopardize health; standard requests processed within 72 hours when complete.
    Step Therapy

    Step Therapy Applies — Prescribe/Document Prerequisite Trials

    Step therapy (ST) applies to numerous formulary items. Where a product is noted with 'ST' or step edits, coverage requires prior use of prerequisite FDA‑approved drugs (the plan does not publish a specific algorithm in this document). Prescribers should document prior therapies tried and reasons for failure or intolerance to meet step therapy requirements. Common examples include DPP‑4 combinations, certain inhaled asthma products (DULERA), anticonvulsants and some antidiabetic combinations and insulins where ST is indicated.

    • Step therapy applies when the formulary Notes include 'ST' or list prerequisite agents.
    • No explicit step therapy algorithm is provided here; prescribers must document prior trials or request a medical exception.
    • Step therapy examples: JANUMET XR (ST), DULERA (ST), saxagliptin‑metformin er (PA/QL) and certain SGLT2/DPP4 combinations.
    Documentation Required

    Documentation Required for PA / Medical Exceptions

    Provide complete clinical documentation with PA or medical exception requests. This includes diagnosis validation (DX) when required, relevant patient history, prior therapy trials and failures, NDCs for product‑specific coverage, and any supporting labs or notes. Missing or incomplete information is a common denial trigger.

    • Prescribers must provide clinical rationale and documentation to support PA/medical exceptions.
    • When DX is required in the Notes, include the diagnosis code and any requested clinical validation.
    • Provide the NDC when coverage is limited to approved products or NDCs are listed.
    • Follow all Notes flags: PA, ST, QL, BH, CB, AL, DX, NDS, SP as applicable to avoid denials.
    Billing Rule

    Benefit-Based Coverage Controls and Flags

    Benefit‑based coverage controls (BH, CB, QL, AL, NDS, SP) are applied across the Formulary and impact PA decisions and point-of-sale coverage. Providers must follow note flags and stated limits; exceeding QLs or missing PA/ST can result in claim denial or request for additional information.

    • BH indicates behavioral‑health related coverage rules (may include zero cost‑share in some plans).
    • CB indicates copay cap rules (e.g., insulin $25 cap) and must be documented where applicable.
    • QL (quantity limits) and AL (age limits) must be adhered to; requests exceeding these require justification via PA.
    • NDS (non‑standard dispensing/special handling) and SP (specialty) flags denote specialty or non-routine distribution requirements.
    Denial Risk

    PA and Quantity Limit (QL) Triggers

    PA and QL triggers — many products are subject to quantity limits and PA; exceeding QL or bypassing PA may prompt utilization review or denial. Copay cap (CB) documentation also applies for insulins and must be considered when processing claims.

    • Quantity Limits (QL) are specified per product (daily, per 30 days, per year); observe and document any requests exceeding those limits.
    • Copay cap (CB) for preferred insulins must be applied and documented per plan rules.
    • Requests that present PA+QL conflicts require prescriber justification and may be subject to denial without adequate documentation.
    Prior Authorization

    Prior Authorization and Age-Based Limits

    PA for age‑specific use: Several products include age limits (AL) or are not covered under certain ages. Examples include codeine- and opioid-containing cough/cold products, tramadol (pediatric age restrictions), and many behavioral health agents requiring PA for patients under defined ages. Prescribers must confirm patient age and include age‑appropriate justification when requesting PA.

    • Not covered for patients under specified ages — do not submit PA unless plan Notes permit (e.g., some codeine products not covered <12 years).
    • PA required for adolescent age group (e.g., 12–18) for certain opioid/cough products — include age in the request.
    • Some long‑acting injectables and intramuscular products have minimum age requirements (AL) listed; verify prior to submission.
    Prior Authorization

    PA for Specialty and Oncology Drugs — DX and NDCs Required

    Specialty and oncology agents frequently require PA plus diagnosis validation and may be limited to specific covered products/NDCs. Prescribers should supply diagnosis, staging or indication details, requested regimen, prior therapies, and NDCs when the Notes require coverage only for approved products.

    • Many antineoplastics list PA and DX (Diagnosis Validation Required) — include clinical oncology documentation.
    • Coverage often limited to approved NDCs; see product Notes (e.g., AMJEVITA covered NDCs).
    • Specialty flags (SP) and non‑standard dispensing (NDS) may necessitate specialty pharmacy routing.
    Denial Risk

    Denial Risk — Follow PA/ST/DX and Documentation Requirements

    Denial risk if PA/ST/DX/documentation missing: Requests that do not meet PA, step therapy, quantity, age, diagnosis validation, or required documentation criteria will be denied. Ensure full adherence to formulary Notes and submit all requested information to reduce adverse determinations.

    • Denials are common when prior authorization is not obtained for PA‑flagged drugs or when step therapy prerequisites are unmet.
    • Incomplete clinical information, missing DX, or not providing required NDCs can trigger adverse determinations.
    • Expedite requests only when medically necessary — otherwise follow standard 72‑hour processing timelines.

    Initiation and Pediatric Initiation Controls

    Pediatric initiation constraints

    Pediatric initiation constraints for certain opioid‑containing and related products:

    Acetaminophen‑codeine and codeine‑containing products (pediatrics): Not covered for patients under 12 years of age. For patients aged 12–18 years, prior authorization is required for initiation of therapy; quantity limits and minimum age annotations apply per product line.age <12 => not covered; age 12-18 => PA

    Examples and exact QLs are listed on product lines (see acetaminophen‑codeine solution/tablet entries).

    Initiation controls

    Initiation controls captured in formulary notes govern access at start of therapy:

    Initial therapy PA/ST requirements: Certain agents require prior authorization at initiation (PA) and some agents or classes require step therapy (ST) — prescribers must document trials of prerequisite agents or provide clinical justification per the ST/PA requirements shown on the formulary line.

    Examples: selected GLP‑1/GIP agents require PA and QL (e.g., QL 2 mL per 28 days); select oral antidiabetics and combinations are marked ST with specified QLs.

    Step Therapy Rules and Examples

    Step therapy definitionNotes
    Step therapy requires prior use of one or more FDA‑approved prerequisite drugs that treat the same condition before covering a step‑therapy medication.Prerequisite drugs are specified by the plan; prescribers must document trial and failure or contraindication to those agents when submitting requests.
    Step therapy promotes use of equally effective lower‑cost formulary drugs first; coverage of the requested drug is contingent on meeting ST requirements.ST is applied as noted on formulary product lines; when ST applies, documentation of prior drug trials is required for approval.
    Presence of explicit algorithmNotes
    No explicit multi‑step algorithm is specified in the extracted formulary chunks.Many products instead rely on prior authorization (PA), diagnosis validation (DX), quantity limits (QL), age limits (AL), or specialty pharmacy (SP) flags as the primary utilization controls.
    When an explicit ST sequence is not provided, PA and DX requirements should be followed as indicated in the product Notes.Absence of a detailed algorithm means prescribers must follow product‑level Notes and contact the plan for required prerequisite agents if unclear.
    Class / examplesNotes
    Certain extended‑release (ER) opioid products (e.g., morphine ER, oxymorphone ER)Formulary Notes indicate ST applies to some ER opioid formulations; Schedule II products also have a 34‑day supply maximum.
    Selected ER opioids listed with 'ST' in product NotesWhere ST applies, prior use of prerequisite opioid therapy as defined by the plan is required; PA and QL also commonly apply.
    Example productST / Notes
    DULERA inhalation aerosolNotes = ST; QL (13 GM per 30 days).
    XOLAIR (example in doc)Listed with utilization controls; ST flag appears on multiple agents in this class.
    clobazam (oral suspension and tablets)Notes = ST; QL (8 mL per 1 day for suspension; 2 EA per 1 day for tablets).
    diazepam rectal gelNotes = ST; BH; QL (5 EA per 30 days); AL.
    NAYZILAM nasal solutionNotes = QL (10 Delivery Systems per 30 days); ST flag appears on related anticonvulsant entries.
    VALTOCO nasal liquid / therapy packsNotes = ST; QL (10 EA per 30 days or 5 packs per 30 days depending on strength); AL (Min 2 Years).
    Products annotated 'ST'Specific step therapy requirement (summary)
    clobazam (oral suspension, tablets)Notes indicate ST; prescriber must document trial/failure of prerequisite agents; QL specified (suspension 8 mL/day; tablets 2 EA/day).
    diazepam rectal gelAnnotated ST; documentation of prior trials required; QL 5 EA per 30 days; BH note present.
    lacosamide oral solutionNotes = ST; QL (1200 mL per 30 days) for solution formulation.
    VALTOCO (various strengths/packs)Notes = ST; QL varies by formulation (10 EA or 5 packs per 30 days); minimum age requirements apply.
    Other anticonvulsants referenced with STWhen ST is annotated, plan requires trial of specified prerequisite agent(s) before covering the ST drug.
    DPP‑4 / combinationsST / Notes
    JANUMET XR (sitagliptin‑metformin XR) / alogliptin‑metformin combinationsNotes = ST (JANUMET XR = ST; alogliptin‑pioglitazone combos = ST); QL examples (JANUMET XR QL 60 EA per 30 days).
    saxagliptin‑metformin ER combinationsNotes = PA; some DPP‑4 inhibitors and combinations are annotated ST or PA per formulary lines.
    Oral antidiabetics / antiemeticsST / Notes
    Steglujan, dapagliflozin, Steglatro, SeglurometNotes = ST on multiple oral antidiabetic combinations; QL commonly 30 EA per 30 days (Steglujan, dapagliflozin examples).
    Granisetron / ondansetron / aprepitant (antiemetics)Some antiemetics (e.g., granisetron noted elsewhere) and aprepitant entries show ST or PA; ondansetron noted with QL (90 EA per 30 days).
    ST enforcementSupporting note
    Where product Notes include 'ST', step therapy edits are enforced at claim/authorization processing.Prescribers must document prior use/failure of required prerequisite agents or provide justification for medical exception.
    If ST is absent but PA/DX flags present, PA/DX remain primary controls.No universal step sequence specified in this extract; follow product‑level Notes for required prerequisites.
    Oral oncology agentsST / Notes
    Some oral oncology agents (examples: VENCLEXTA, erivedge, daurisimo) note PA and DX; QLs are listed per product.No explicit multi‑step ST algorithm is present for oral oncology agents in these chunks; PA and DX are the primary utilization controls.
    Specialty handling flags (NDS, SP) and QL often accompany PA/DX for oral oncology agents.When step edits are needed, the plan will specify them on the product line; none are detailed here.
    Specialty oncology agentsImplication
    Multiple specialty oncology agents are marked with PA, DX, NDS, and SP (e.g., LENVIMA, INLYTA, ALECENSA).These flags imply specialty pathways and required documentation but do not provide explicit step therapy sequencing in this excerpt.
    Prescribers must submit diagnosis validation and follow PA requirements for approval.Quantity limits and specialty pharmacy handling are common controls for these agents.
    sacubitril‑valsartan (Entresto)ST / QL
    sacubitril‑valsartan oral tabletNotes = ST; QL (60 EA per 30 days). ENTRESTO sprinkle noted as PA; sacubitril‑valsartan explicitly annotated 'ST' indicating step therapy applies.
    Guaifenesin‑codeine / cough productsCoverage / PA / Age limits
    guaifenesin‑codeine oral solution / G Tussin AC / guaiatussin ACNotes = PA; Not covered for patients under 12 years of age. Prior authorization required for patients 12–18; AL Min 12 Years specified.
    Guaifenesin‑codeine oral solution (100‑10 mg/5 mL) examplesCoverage requires prior authorization for ages 12–18 and is not covered for <12 years. Documentation must support PA per formulary Notes.

    Quantity Limits and Per-Product Examples

    inv-179: Multiple individual formulary drugs — examples: 30 EA/30 days; 60 EA/30 days; 120 EA/30 days; 14 EA/7 days; 1 EA/day
    30 EA / 30 daysExample common QL: 30 EA per 30 days
    60 EA / 30 daysExample common QL: 60 EA per 30 days
    120 EA / 30 daysExample common QL: 120 EA per 30 days
    14 EA / 7 daysExample short-interval QL: 14 EA per 7 days
    1 EA per dayDaily unit limit example: 1 EA per day (e.g., certain anorexiants/phentermine)
    inv-180: Preferred formulary insulin — $25 copay cap
    Preferred formulary insulin copay capPreferred formulary insulin: copay not to exceed $25 per 30-day supply
    Applies across insulin brands/formsCopay cap noted on multiple insulin product lines (pens/cartridges/solutions)
    HDHP applicationHigh Deductible Health Plan members subject to deductible first though cap remains in language
    inv-181: AMJEVITA subcutaneous solution — QL (1.6 ML per 28 days)
    AMJEVITA QL (auto-injector 0.4 mL)QL 1.6 mL per 28 days for AMJEVITA 40 mg/0.4 mL presentations
    AMJEVITA covered NDCsCoverage applies to approved products only; specific covered NDCs are listed on formulary (see product line)
    DX and specialty flagsAMJEVITA entries include DX (Diagnosis Validation Required) and SP/NDS flags
    inv-182: HUMIRA various presentations — QL (2 EA per 28 days) or as listed
    HUMIRA QLHUMIRA presentations: QL 2 EA per 28 days (or as listed by presentation)
    PA and DXHUMIRA lines include PA and DX (Diagnosis Validation Required) and flags for NDS and SP
    Presentation-specific QLsSome HUMIRA kits/pens list alternative QLs (e.g., 1 kit per 28 days) per presentation
    inv-183: TYENNE — QL (3.6 ML per 28 days)
    TYENNE QLTYENNE subcutaneous presentations: QL 3.6 mL per 28 days
    PA/DX/SP flagsTYENNE entries include PA; DX (Diagnosis Validation Required); SP/NDS as applicable
    IV formulations notedTYENNE IV presentations listed (MB tier) with PA/DX flags per product
    inv-184: OTEZLA 30 mg — QL (60 EA per 30 days)
    OTEZLA QLOTEZLA (apremilast) 30 mg oral tablet: QL 60 EA per 30 days
    PA and DXOTEZLA line notes include PA and DX (Diagnosis Validation Required); NDS and SP flags
    Therapy packOTEZLA therapy pack entries reference same QL (60 EA per 30 days)
    inv-185: Stimulant agent QLs — range 30–120 EA per 30 days depending on formulation
    Stimulant QL rangeStimulant agents (e.g., armodafinil, methylphenidate) show QLs ranging from 30 to 120 EA per 30 days depending on formulation
    Age limits and PAMany stimulant entries include AL (minimum age) and PA notes for select formulations
    Formulation-specific QLsExamples across entries: QL 30 EA/30 days; QL 60 EA/30 days; QL 120 EA/30 days
    inv-189: Morphine sulfate ER beads/capsules — QL (30)
    Morphine sulfate ER QLMorphine sulfate ER beads/capsules: QL 30 (EA per 30 days) noted for selected formulations
    ST and Schedule II notesMorphine ER entries include ST; Schedule II formulary lines reference the 34-day supply maximum
    Various strengths listedMultiple strengths/formulations of morphine ER appear with corresponding QLs
    inv-190: Schedule II medications — 34 day supply maximum
    Schedule II maximum days' supplySchedule II medications are limited to a 34 day supply maximum
    Opioid examplesSchedule II notation appears with various ER opioid entries (e.g., morphine, oxymorphone) in product notes
    Documentation requirementPrescribers should document prescription schedule and days' supply to comply with the limit
    inv-191: Multiple QL examples as listed across product groups (e.g., 135 EA/30 days, 120 EA/30 days, 90 EA/30 days)
    Multiple QL examplesExamples across product groups include QL 135 EA/30 days, 120 EA/30 days, 90 EA/30 days (benzodiazepines, antiepileptics, others)
    Inhaler/gram QLsSome respiratory agents use gram limits (e.g., QL 20.4 GM per 30 days; QL 8 GM per 30 days)
    Starter packsStarter/therapy packs use time-based QLs (e.g., QL 74 EA per 365 days for certain starter packs)
    inv-192: clobazam oral suspension — 8 ML
    Clobazam oral suspension QLClobazam oral suspension 2.5 mg/mL: QL 8 mL per 1 day
    Clobazam oral tablet QLClobazam oral tablet 10/20 mg: QL 2 EA per 1 day
    Highlight — clobazam suspension limitClobazam oral suspension QL 8 mL per day (noted on formulary)
    inv-193: clobazam oral tablet — 2 EA
    Clobazam tablet QLClobazam oral tablet (10 mg, 20 mg): QL 2 EA per 1 day
    ST/notesClobazam tablet entries include ST and QL flags as indicated on product lines
    Behavioral health noteMany clobazam entries include BH notation (behavioral health) where applicable
    inv-194: diazepam rectal gel — 5 EA
    Diazepam rectal gel QLDiazepam rectal gel: QL 5 EA per 30 days
    ST/BH notesDiazepam rectal gel line includes ST and BH flags where applicable
    Pediatric/age limitsSome rectal gel entries include AL notes in formulary lines
    inv-195: NAYZILAM nasal solution — 10 delivery systems
    NAYZILAM QLNAYZILAM nasal solution 5 mg/0.1 mL: QL 10 delivery systems per 30 days
    Indications/notesNAYZILAM entries include BH and ST notes as applicable
    Packaging-specific QLQL referenced as delivery systems per 30 days (product-specific)
    inv-196: VALTOCO — 10 EA or 5 packs depending on strength
    VALTOCO QL (single doses)VALTOCO 10 mg dose nasal liquid: QL 10 EA per 30 days
    VALTOCO therapy pack QLVALTOCO therapy packs (e.g., 2x7.5 mg) QL 5 packs per 30 days depending on strength
    Highlight — VALTOCO dose/pack limitsVALTOCO: QL 10 EA or 5 packs per 30 days depending on strength (AL Min 2 Years noted)
    inv-197: lacosamide oral solution — 1200 ML
    Lacosamide oral solution QLLacosamide oral solution 10 mg/mL: QL 1200 mL per 30 days
    ST noteLacosamide oral solution entry includes ST flag where noted
    Tablet QL comparisonLacosamide tablets: QL 60 EA per 30 days (formulation-dependent)
    inv-198: levetiracetam ER oral tablet — 120 EA
    Levetiracetam ER QLLevetiracetam ER oral tablet: QL 120 EA per 30 days
    Formulation noteDifferent levetiracetam formulations carry specific QLs (tablets vs solution)
    Behavioral health noteSome anticonvulsant entries include BH notation as applicable
    inv-199: pregabalin oral capsule — 60 EA
    Pregabalin QLPregabalin oral capsule: QL 60 EA per 30 days
    BH notationPregabalin entries include BH notation for behavioral health where applicable
    Multiple strengthsQL applies across multiple strengths/formulations listed
    inv-200: felbamate oral suspension — 900 ML
    Felbamate suspension QLFelbamate oral suspension: QL 900 mL per 30 days
    Tablet QLFelbamate tablets show QLs (e.g., 90–180 EA per 30 days depending on strength)
    Formulation distinctionDifferent felbamate forms (suspension vs tablet) have distinct QLs noted
    inv-201: paroxetine hcl oral tablet — 30 EA per 30 days (example)
    Paroxetine tablet QLParoxetine HCl oral tablet (some strengths): QL 30 EA per 30 days (example)
    Paroxetine suspension PAParoxetine oral suspension: PA noted for some presentations
    Formulation notesParoxetine QLs vary by formulation/strength as listed in formulary
    inv-202: venlafaxine hcl er — 2 EA per day (example)
    Venlafaxine ER dosing QLVenlafaxine HCl ER oral capsule: example QL 2 EA per day
    SNRIs class QLsSNRIs entries include QLs such as 60 EA per 30 days for some venlafaxine products
    BH notationMany SNRI entries include BH notes where applicable
    inv-203: Insulin product examples and QLs (Humalog, Humulin, insulin aspart, insulin glargine-yfgn, insulin lispro)
    Insulin product QL examplesInsulin examples include QL 45 mL per 30 days; QL 50 mL per 30 days; QL 18 mL per 30 days for U-500 Kwikpen
    Products citedExamples include Humalog, Humulin, insulin aspart, insulin glargine-yfgn, insulin lispro among others
    Copay cap referenceThese insulin product lines also reference the preferred insulin copay cap (CB) of $25/30 days
    inv-204: desvenlafaxine succinate ER — QL 30 EA per 30 days
    Desvenlafaxine QLDesvenlafaxine succinate ER: QL 30 EA per 30 days
    BH noteEntry includes BH notation where applicable
    TieringDesvenlafaxine appears in formulary with tier and QL indicated
    inv-205: JANUMET / alogliptin-metformin combos — QL 60 EA per 30 days (example)
    JANUMET / alogliptin-metformin QLJANUMET (alogliptin‑metformin combos) example QL 60 EA per 30 days
    ST/PA notesSome DPP‑4/metformin combination lines include ST or PA flags as annotated
    Formulary exampleQL shown as example for combination oral antidiabetics (60 EA per 30 days)
    inv-206: Various insulins (pen/cartridge/solution) — 45 mL or 50 mL per 30 days
    Insulin pen/cartridge/solution QLsCommon QLs for pen/cartridge/solution insulins: 45 mL or 50 mL per 30 days (product-dependent)
    U-500 QL exampleU-500 Kwikpen: QL 18 mL per 30 days (specific high-concentration insulin example)
    Copay cap cross-referenceThese product lines reference the preferred insulin copay cap (CB $25/30 days)
    inv-207: Example GLP-1s (Mounjaro, Trulicity) — QL 2 mL
    GLP-1 example QLGLP‑1 agents (e.g., Mounjaro, Trulicity): QL 2 mL per 28 days
    PA noteEntries for these incretin mimetic agents include PA and NDS flags as indicated
    Product examplesMounjaro and Trulicity listed with QL 2 mL per 28 days in formulary
    inv-208: Vivitrol — 1 EA
    Vivitrol QLVivitrol (naltrexone long‑acting injection): QL 1 EA (per dosing interval)
    PA/administration notesVivitrol entries include site/administration and QL notes as applicable
    Formulary tieringVivitrol appears with tier and QL indicated in formulary list
    inv-209: Ondansetron — 90 EA
    Ondansetron QLOndansetron oral dispersible tablets (4 mg, 8 mg): QL 90 EA per 30 days
    Palonosetron IV QLPalonosetron IV 0.25 mg/2 mL: QL 2 mL per 5 days
    Emend oral suspension QLEMEND oral suspension reconstituted 125 mg/5 mL: QL 6 EA per 28 days
    inv-211: EMEND oral suspension reconstituted — 6 EA
    EMEND oral suspension QLEMEND oral suspension reconstituted 125 mg/5 mL: QL 6 EA per 28 days
    EMEND IV noteEMEND IV is Tier MB and requires PA
    NK1 antagonist packagingAprepitant entries include PA and QL (1–3 EA per 30 days depending on pack)
    inv-212: palonosetron IV 0.25 mg/2ml — 2
    Palonosetron IV QLPalonosetron HCl IV 0.25 mg/2 mL: QL 2 (ML per 5 days)
    MB tierPalonosetron IV listed as MB tier with QL specified
    CINV agent notesAnti‑emetic IV agents often require PA and have defined QLs per treatment course
    inv-213: atorvastatin calcium oral tablet — 30
    Atorvastatin QLAtorvastatin calcium oral tablet: QL 30 EA per 30 days
    $0 tier noteAtorvastatin listed at $0 tier in formulary where applicable
    Common cholesterol QLStatin entries commonly use QL 30 EA per 30 days for maintenance fills
    inv-214: XIFAXAN 200 mg — 9
    XIFAXAN 200 mg QLXIFAXAN 200 mg oral tablet: QL 9 EA per 30 days
    XIFAXAN 550 mg QLXIFAXAN 550 mg oral tablet: QL 60 EA per 30 days
    Indication-specific packsQ L varies by indication/strength — e.g., hepatic encephalopathy vs IBS-D dosing
    inv-215: XIFAXAN 550 mg — 60
    XIFAXAN 550 mg QLXIFAXAN 550 mg: QL 60 EA per 30 days
    PA/ST notesCertain XIFAXAN entries may include PA depending on indication
    Treatment-course QLsDifferent strengths reflect differing QLs aligned to typical treatment courses
    inv-216: vancomycin 125 mg capsule — 56
    Vancomycin 125 mg QLVancomycin HCl oral capsule 125 mg: QL 56 (per 14 days)
    Vancomycin 250 mg QLVancomycin HCl oral capsule 250 mg: QL 80 EA per 30 days
    Vancomycin solution QLVancomycin oral solution (25/50 mg/mL): QL 300 mL per 14 days
    inv-217: vancomycin 250 mg capsule — 80
    Vancomycin 250 mg QLVancomycin HCl oral capsule 250 mg: QL 80 EA per 30 days
    PA noteSome vancomycin capsule entries include PA per formulary notes
    Oral solution QLOral solution QL 300 mL per 14 days for reconstituted formulations
    inv-218: vancomycin oral solution — 300 mL
    Vancomycin oral solution QLVancomycin oral solution reconstituted 25/50 mg/mL: QL 300 mL per 14 days
    Use-case noteSolution QL reflects pediatric/weight‑based preparations and reconstitution volumes
    Formulary tieringSolution may be tiered differently (MB/2/3) depending on product line
    inv-219: abiraterone acetate 250 mg — QL 120 EA per 30 days
    Abiraterone QLAbiraterone acetate 250 mg oral tablet: QL 120 EA per 30 days
    PA/DX flagsEntry includes QL and may be subject to PA/DX as oncology agent
    Specialty handlingOncology agents often include SP/NDS indications alongside QL
    inv-220: ALECENSA 150 mg — QL 240 EA per 30 days
    ALECENSA QLALECENSA (alectinib) 150 mg oral capsule: QL 240 EA per 30 days
    PA/DX/LA flagsALECENSA entry includes PA, LA, DX and other specialty flags
    NDS/Specialty noteTherapy packs and specialty oncology entries may list NDS/SP alongside QL
    inv-221: VENCLEXTA various strengths — QL 30-120 EA per 30 days depending on strength
    VENCLEXTA QL rangeVENCLEXTA (venetoclax) QL varies by strength/pack: QL 30–120 EA per 30 days depending on strength
    PA/DX/LA notesVENCLEXTA entries include PA, DX and potentially LA (limited access) flags
    Oncology packaging impactPack/strength determines monthly QL (varies by treatment regimen)
    inv-222: DAURISMO 100 mg — 30 EA
    DAURISMO 100 mg QLDAURISMO 100 mg oral tablet: QL 30 EA per 30 days
    DAURISMO 25 mg QLDAURISMO 25 mg oral tablet: QL 60 EA per 30 days
    PA/DX/SPDAURISMO includes PA, DX and SP flags as oncology agent
    inv-223: DAURISMO 25 mg — 60 EA
    DAURISMO 25 mg QLDAURISMO 25 mg: QL 60 EA per 30 days
    Oncology PA/DXDAURISMO entries include PA and DX requirements and SP where applicable
    Treatment pack noteQLs reflect typical dosing schedules per indication
    inv-224: ERIVEDGE 150 mg — 30 EA
    ERIVEDGE QLERIVEDGE 150 mg oral capsule: QL 30 EA per 30 days
    PA/DX/SP notesERIVEDGE includes PA, DX and SP flags as oncology agent
    Formulation/pack noteQL aligns with standard monthly treatment quantities
    inv-225: ZOLINZA 100 mg — 120 EA
    ZOLINZA QLZOLINZA 100 mg oral capsule: QL 120 EA per 30 days
    PA/DX flagZOLINZA listing includes PA and DX as oncology/dermatology agent
    Specialty noteMay require specialty handling (SP/NDS) per formulary line
    inv-226: pomalidomide — 21 EA
    Pomalidomide QLPomalidomide oral capsule: QL 21 EA per 28 days
    PA/NDS/SPPomalidomide entries include PA, NDS and SP flags as required
    Regimen-based QLQL structured to align with cycle-based oncology regimens (28‑day cycles)
    inv-227: KRAZATI 200 mg — 180 EA
    KRAZATI QLKRAZATI 200 mg oral tablet: QL 180 EA per 30 days
    PA/LA/DX flagsEntry includes PA, LA and DX requirements and NDS where indicated
    Specialty handlingOncology agent may be managed via specialty pharmacy (SP)
    inv-228: LUMAKRAS 120 mg — 240 EA
    LUMAKRAS 120 mg QLLUMAKRAS 120 mg oral tablet: QL 240 EA per 30 days
    LUMAKRAS 320 mg QLLUMAKRAS 320 mg oral tablet: QL 3 EA (per 1 day) — pack/strength dependent
    PA/DX/SP notesLUMAKRAS lines include PA, DX and SP flags per formulary
    inv-229: LUMAKRAS 320 mg — 3 EA
    LUMAKRAS 320 mg QLLUMAKRAS 320 mg: QL 3 EA per 1 day (specific high‑strength pack limit)
    PA/DX requirementPA and DX required for high‑cost oncology agents as noted
    Pack-based QLHigh‑strength tablets often have very low QLs reflecting single‑use dosing
    inv-230: MEKINIST 0.5 mg — 90 EA
    MEKINIST 0.5 mg QLMEKINIST 0.5 mg oral tablet: QL 90 EA per 30 days
    MEKINIST 2 mg QLMEKINIST 2 mg oral tablet: QL 30 EA per 30 days
    PA/DX/SPMEKINIST entries include PA, DX and SP flags as oncology agent
    inv-231: MEKINIST 2 mg — 30 EA
    MEKINIST 2 mg QLMEKINIST 2 mg: QL 30 EA per 30 days
    Therapy pack noteDifferent strengths/packings result in differing QLs per 30 days
    Oncology PA/DXPA and DX frequently required for MEKINIST formulations
    inv-232: CABOMETYX — 30 EA
    CABOMETYX QLCABOMETYX oral tablet: QL 30 EA per 30 days
    PA/DX/SPCABOMETYX listing includes PA, DX and SP flags as oncology agent
    Dose-pack notesTherapy pack options influence monthly QL as indicated in product lines
    inv-233: CAPRELSA 100 mg — 60 EA
    CAPRELSA QLCAPRELSA (vandetanib) 100 mg oral tablet: QL 60 EA per 30 days
    PA/LA/DX flagsCAPRELSA includes PA, LA and DX requirements in formulary notes
    NDS/Specialty noteMay be managed via specialty pharmacy; pack/therapy flags indicated
    inv-234: RYDAPT for AML — 120 EA
    RYDAPT QL for AMLRYDAPT (midostaurin) for AML: QL 120 EA per 30 days
    Multiple indication QLsRYDAPT QL differs for other indications (e.g., ASM, SM, AHN, MCL up to 240/30) — see product notes
    PA/DX requirementPA and DX required for antineoplastic agents as indicated
    inv-235: XPOVIO therapy pack — 8 EA
    XPOVIO therapy pack QLXPOVIO 100 mg once‑weekly therapy pack: QL 8 EA per 28 days
    Other XPOVIO pack QLsOther weekly/dose packs: QL examples include 4 packs per 28 days for some schedules
    PA/LA/DXXPOVIO entries include PA, LA, DX and NDS flags per therapy pack
    inv-236: XPOVIO various weekly/dose packs — 4 packs
    XPOVIO weekly pack QLsVarious XPOVIO weekly/dose packs: examples include QL 4 packs per 28 days depending on schedule/strength
    Regimen-specific limitsPack QLs reflect dosing schedules (weekly, twice-weekly) and are listed per pack type
    Utilization flagsPA/LA/DX and NDS flags accompany pack listings as noted
    inv-237: INLYTA — 120 EA
    INLYTA QLINLYTA (axitinib) oral tablet: QL 120 EA per 30 days
    PA/DX/SPINLYTA listing includes PA, DX and SP flags as oncology agent
    Pack/therapy noteTherapy packs and dosing schedules influence QLs for multikinase inhibitors
    inv-238: LENVIMA therapy pack — 30-90 EA
    LENVIMA therapy pack QLsLENVIMA therapy packs: QLs vary by pack/strength (examples: 30–90 EA per 30 days)
    PA/DX/SP flagsLENVIMA entries include PA, DX, NDS and SP notes as applicable
    Dose-dependent QLsPack strength determines monthly QL (30, 60, 90 EA per 30 days depending on pack)
    inv-239: INVEGA SUSTENNA/TRINZA — per product-specific mL per dosing interval
    INVEGA SUSTENNA/TRINZA QLsINVEGA SUSTENNA/TRINZA: QLs stated per product-specific mL per dosing interval (e.g., 0.75 mL per 28 days; 1.75 mL per 84 days)
    BH/AL notesSome long‑acting injectables include BH and AL flags (minimum age) alongside QLs
    NDS/SPNDS and SP flags may apply per product line for injection formulations
    inv-240: CAPLYTA — 30 EA
    CAPLYTA QLCAPLYTA oral capsule: QL 30 EA per 30 days
    PA/AL notesCAPLYTA has PA and AL (Min 18 Years) flags noted in formulary
    Use-caseQL aligns with chronic maintenance dosing as indicated
    inv-241: risperidone oral solution — 480 mL
    Risperidone oral solution QLRisperidone oral solution: QL 480 mL per 30 days
    PA/AL notesPA required for patients younger than certain ages; AL Min 5 Years noted for some formulations
    BH designationMany risperidone lines include BH zero-cost-share notation where applicable
    inv-242: ABILIFY MAINTENA — 3 EA per 84 days
    ABILIFY MAINTENA QLABILIFY MAINTENA IM prefilled syringe: QL 3 EA per 84 days
    PA/BH/AL notesABILIFY MAINTENA requires PA and includes BH and AL (Min 18 Years) flags
    Long‑acting injectable handlingLong‑acting injectables list QLs per dosing interval (e.g., per 84 days) and may require PA
    inv-243: aripiprazole oral solution — 750 mL per 30 days
    Aripiprazole oral solution QLAripiprazole oral solution: QL 750 mL per 30 days
    PA/AL notesSome aripiprazole lines require PA for young children and include AL minimum ages
    BH notationEntries include BH zero-cost-share notes where applicable
    inv-244: various antiretroviral tablet examples — commonly 30 EA per 30 days
    Antiretroviral tablets QLVarious antiretroviral tablets (e.g., Descovy, Biktarvy, Genvoya, Triumeq): common QL 30 EA per 30 days where noted
    STI/$0 copay noteMany antiretroviral entries include STI notation indicating coverage at $0 copay for STI/PrEP indications
    PA for new startsSome entries require PA for new starts and DX validation for PrEP indications
    inv-245: Selzentry oral solution — 900 mL per 30 days
    Selzentry solution QLSelzentry oral solution: QL 900 mL per 30 days
    STI/$0 tierSelzentry listed at $0 tier with STI zero-cost-share notation where used for STI indications
    Formulation-specific QLSolution QLs reflect liquid formulations (mL per 30 days)
    inv-246: Isentress — 60/120 (examples)
    Isentress QLsIsentress: QL examples include 60 EA and chewable/tablet 120 EA per 30 days depending on presentation
    $0 tier/STIIsentress entries include STI zero-cost-share notes where applicable
    Pack/presentation differencesQL differs by packet/tablet/chewable form (e.g., 60 vs 120 EA per 30 days)
    inv-247: Tivicay 50 mg — 30
    Tivicay QLTivicay (dolutegravir) 50 mg: QL 30 EA per 30 days
    PD soluble QLPD soluble formulation has QL 180 EA per 30 days for pediatric/PD dosing
    $0 tier/STITivicay listed at $0 tier with STI zero-cost-share notes where applicable
    inv-248: Prezista oral suspension — 360
    Prezista suspension QLPrezista oral suspension: QL 360 mL per 30 days
    Prezista tablet QLPrezista tablets: QL examples include 60 EA per 30 days
    $0 tier/STIMany Prezista entries list $0 tier/STI zero-cost-share where applicable
    inv-249: Viread oral powder — 225
    Viread powder QLViread oral powder: QL 225 GM per 30 days
    Viread tablet QLsViread tablets listed at $0 tier for STI indications; QLs vary by formulation
    STI zero-cost-shareViread entries include STI zero-cost-share language for prevention/treatment uses
    inv-250: PAXLOVID therapy pack — 40; 60
    PAXLOVID therapy pack QLsPAXLOVID therapy packs: QL 40 EA per 365 days (10x150/10x100 pack) and 60 EA per 365 days for alternate pack
    TieringPAXLOVID listed as Tier 3 with pack‑based QLs
    Pack‑specific limitsQLs based on pack size and annual limits per formulary notes
    inv-251: oseltamivir capsules/suspension — various QLs depending on strength
    Oseltamivir QLsOseltamivir capsules/suspension: QLs vary by strength (examples: 10–20 EA; suspension 180 mL per 180 days)
    Seasonal/stock QLsDifferent QLs reflect prophylactic vs treatment pack sizes and timeframes (180‑day examples present)
    Formulary examplesCapsule QL 10 EA per 180 days for some strengths; suspension QL 180 mL per 180 days
    inv-252: verapamil ER 180 mg — QL 60 EA per 30 days
    Verapamil ER QLVerapamil HCl ER 180 mg: QL 60 EA per 30 days
    ER product QLsExtended‑release cardiovascular agents show monthly QLs (e.g., 60 EA per 30 days)
    Formulary contextQL aligns with chronic therapy maintenance fills for ER cardiac drugs
    inv-253: ENTRESTO sprinkle — QL 60 EA per 30 days
    ENTRESTO sprinkle QLENTRESTO oral capsule sprinkle: QL 60 EA per 30 days (Notes = PA)
    sacubitril-valsartan QLSacubitril‑valsartan oral tablet: QL 60 EA per 30 days (ST noted for some entries)
    PA/ST flagsEntries include PA or ST flags as indicated (ENTRESTO = PA; sacubitril‑valsartan = ST)
    inv-254: sacubitril-valsartan — QL 60 EA per 30 days
    Sacubitril‑valsartan QLSacubitril‑valsartan: QL 60 EA per 30 days; some listings marked ST (step therapy)
    ENTRESTO sprinkle PAENTRESTO sprinkle entry specifically notes PA requirement
    Formulary applicationST/PA flags indicate utilization controls that must be followed for coverage
    inv-255: ambrisentan — QL 30 EA per 30 days
    Ambrisentan QLAmbrisentan oral tablet: QL 30 EA per 30 days
    PA/NDS/SPAmbrisentan entry includes PA, NDS and SP flags in formulary notes
    Pulmonary hypertension contextQL aligns with chronic dosing schedules for PAH agents
    inv-256: sildenafil citrate — QL 90 EA per 30 days
    Sildenafil QLSildenafil citrate oral tablet: QL 90 EA per 30 days
    PA noteSome sildenafil entries may include PA for certain indications
    Pack/month supplyQL consistent with monthly supply limits for chronic PDE5 therapies
    inv-257: amlodipine-atorvastatin — QL 30 EA per 30 days
    Amlodipine‑atorvastatin QLAmlodipine‑atorvastatin oral tablet: QL 30 EA per 30 days
    Combination product noteCombination cardiovascular agents follow standard monthly QLs for maintenance therapy
    Formulary listingQL 30 per 30 days cited for combination antihypertensive/statin products
    inv-258: Budesonide 3 mg — 448 EA per 365 days
    Budesonide DR annual QLBudesonide oral capsule delayed release particles 3 mg: QL 448 EA per 365 days
    Yearly limit contextAnnual QL specified for chronic corticosteroid product (per 365 days)
    Formulary tierBudesonide DR listed with tier and annual QL for supply control

    Site of Care and Specialty Pharmacy Handling

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Key Terms and Abbreviations

    inv-125: Formulary / Closed Formulary definition
    Formulary definitionFormulary: a continually updated list of medications supported by evidence-based medicine; closed formulary means non‑Formulary drugs are not routinely reimbursed without a medical exception
    Closed formulary implicationNon‑Formulary drugs require medical exception/prior authorization to be reimbursed
    PurposeDesigned to encourage safe, effective, and cost‑efficient medication use
    inv-126: Prior Authorization definition
    Prior Authorization definitionPrior authorization: clinical evaluation process to determine medical necessity and coverage before services are provided
    ReviewersRequests reviewed by Medical Director or other clinical professional for medical necessity
    Applies to many formulary drugsPA noted on numerous product lines and is required before coverage when indicated
    inv-127: Step Therapy definition
    Step Therapy definitionStep therapy: requires prior use of one or more FDA‑approved prerequisite drugs that treat the same condition before covering the step‑therapy medication
    PurposePromotes use of equally effective lower‑cost formulary drugs first
    Prerequisite specificationPrerequisite drugs are FDA‑approved and specified by the plan
    inv-128: Quantity Limit definition
    Quantity Limit definitionQuantity limits: limits on maximum daily dose or number of units over a defined period to promote safe and appropriate use
    TypesIncludes Maximum Daily Dose (per day) and Quantity Limits Over Time (e.g., EA per 30 days)
    BasisLimits set using medical guidelines and FDA‑approved recommendations
    inv-129: DX (Diagnosis Validation Required)
    DX meaningDX (Diagnosis Validation Required): payer requires documentation of the covered diagnosis to approve the drug
    ApplicationDX commonly applied to biologics, oncology, and select specialty agents (e.g., AMJEVITA, HUMIRA, oncology agents)
    Submission contextDiagnosis validation required at prior authorization or point of sale where noted
    inv-130: QL (Quantity Limit)
    QL meaningQL (Quantity Limit): maximum quantity allowed per specified time period (e.g., EA per 30 days or mL per 28 days)
    FormatsExpressed as EA per 30 days, ML per 28/30 days, GM per 30 days, or per dosing interval
    EnforcementProducts exceeding stated QLs are subject to utilization review and may be denied without PA or exception
    inv-131: AL (Age Limit)
    AL meaningAL (Age Limit): minimum and/or maximum age restrictions applied to coverage for the drug
    ExamplesFormulary entries include AL Min 2 Years (VALTOCO), Min 5 Years (risperidone), Min 18 Years (CAPLYTA), etc.
    Pediatric implicationsCertain products not covered under 12 years or require PA for ages 12–18 as specified
    inv-133: SP (Specialty Pharmacy)
    SP meaningSP (Specialty Pharmacy): indicates the product is managed through specialty pharmacy processes
    ApplicationMany biologics, oncology, and specialty agents flagged SP require specialty acquisition and handling
    Site implicationsSP flag often accompanies PA, DX, QL and NDS on product lines
    inv-134: ST (Step Therapy)
    ST meaningST (Step Therapy): indicates a step‑therapy requirement as noted on product lines
    ExamplesST appears on select ER opioids and other agents (e.g., morphine ER lines include ST; sacubitril‑valsartan noted ST)
    Provider actionPrescribers must document trial/failure of prerequisite agents per ST rules when required
    inv-145: CB (Copay cap/benefit) — preferred formulary insulin copay cap note
    CB (Copay cap) meaningCB indicates copay cap/benefit (e.g., preferred formulary insulin copay not to exceed $25 per 30‑day supply)
    Insulin applicationCB used on multiple insulin product lines to denote the $25/30‑day cap
    HDHP noteHigh Deductible Health Plan copays/coinsurance apply to deductible first; CB cap language still present
    inv-163: PPACA $0 Copay — preventive contraceptives $0 copay note
    PPACA $0 Copay for contraceptivesMany contraceptive entries note '$0 Copay per PPACA guidelines' and 'Up to a six‑month supply'
    Supply allowanceFormulary lines commonly allow up to a six‑month supply for contraceptives where PPACA applies
    DocumentationDocumentation should support supply and PPACA eligibility as noted in formulary guidance
    inv-151: DX (Diagnosis Validation) — definition and application for oncology agents
    DX for oncology agentsDiagnosis Validation (DX) required: payer requires submission/validation of appropriate diagnosis for many oncology agents (e.g., VENCLEXTA, ALECENSA)
    Application at PA/point of saleDX may be required at prior authorization or at point of sale per product note
    Denial riskFailure to provide DX may result in denial of coverage for product lines requiring DX
    inv-155: MB (Medical Benefit) — definition
    MB definitionMB (Medical Benefit): drug administered by a healthcare professional, typically billed under the medical benefit and given in settings such as home, provider office, infusion suite, or outpatient facility
    ImplicationMB‑tier products may require prior authorization and specialty pharmacy acquisition; site of care influences billing
    ExamplesIV/infusion agents and some long‑acting injectables are listed as MB in the formulary (e.g., palonosetron IV, ABILIFY MAINTENA entries reference MB handling)

    Formulary Purpose and Policy Scope

    A Formulary is a preferred drug list maintained to encourage safe, effective, and cost‑efficient medication use. The plan manages utilization through tools such as prior authorization, step therapy, and quantity limits, applied per product line as indicated by formulary notes and tier assignments.

    Presbyterian operates a closed Formulary, meaning non‑Formulary drugs require a documented medical exception to be reimbursed; reviewers (Medical Director or clinical professional) evaluate medical necessity when exceptions or prior authorization requests are submitted.

    The extracted formulary lines are presented as product entries that show tier, notes, and any quantity or age limits. These segments do not provide separate, standalone medical necessity criteria; instead coverage decisions rely on adherence to the per‑product Notes (for example, PA, ST, QL, AL, and benefit flags) and on documentation submitted with authorization requests.

    Biosimilar Coverage Notes

    Note